Menu Close

Aesthetic injectable companies. L’Oréal and Verily partner to advance skin health

Biorevitalization

THE WHAT? L’Oréal and Verily have announced a strategic partnership, exclusive in beauty, to advance skin health.

THE DETAILS Through two programs, the French beauty giant and Alphabet precision health company are hoping to better understand and characterize skin and hair aging mechanisms and to inform L’Oréal’s precision beauty tech strategy and product development.

Meso Therapy

The first initiative will be a strategic research collaboration to establish a longitudinal biological, clinical, environmental view of skin health and the second will be a partnership between Verily’s R&D team and L’Oréal’s Active Cosmetics division to explore the development of new technologies and tele-diagnosis solutions.

“We recognize skin health as a critical need for overall wellness as it not only impacts us physically in our daily lives, but also holistically. Our collective approach has the potential to identify the right intervention based on data, powered by Verily’s technology and clinical science abilities combined with L’Oréal’s beauty industry leading intelligence and dermatology network” says Brian Otis, Fellow, Co-Founder, Verily.

THE WHY? Nicolas Hieronimus, Chief Executive Officer, L’Oréal Group, reveals, “We are excited to partner with Verily, a world leader in precision health tech.  L’Oréal’s century-long commitment to pioneering innovation has come from our strong belief in the intersection between science, formulations, and our unique Advanced Research capabilities to decode revolutionary scientific discoveries that will create the future of beauty. Thanks to this partnership, we want to lead a new era of skin health, through tech and science, to enable every person around the world the most inclusive, personalized, powerful and precise programs for their skin at each stage of their lives.”

  Aesthetic injectable companies. L’Occitane Group venture capital firm invests in digital-native French lingerie brand Lolo Paris

Aesthetic injectable companies refer to businesses or companies that specialize in manufacturing, distributing, or providing aesthetic injectable products and services. These companies focus on developing and supplying injectable substances used for cosmetic purposes, typically administered by qualified medical professionals. Aesthetic injectable companies play a crucial role in the field of aesthetic medicine and cosmetic dermatology by offering a variety of injectable products designed to enhance facial features, reduce wrinkles, and improve overall skin appearance.

Key aspects of aesthetic injectable companies include:

  • Product Development: These companies research, develop, and manufacture aesthetic injectables such as dermal fillers, botulinum toxins (e.g., Botox), collagen stimulators, and other specialized formulations. They often innovate new products to meet evolving market demands and technological advancements.

  • Distribution and Sales: Aesthetic injectable companies distribute their products through authorized channels, including healthcare providers, medical spas, and aesthetic clinics. They may also sell directly to licensed professionals who administer these treatments.

  • Regulatory Compliance: Due to the medical nature of their products, aesthetic injectable companies adhere to strict regulatory guidelines and obtain necessary approvals from health authorities (e.g., FDA in the United States) to ensure safety, efficacy, and quality standards.

  • Training and Support: Many companies provide training and educational support to healthcare professionals on the proper use, administration techniques, and safety protocols associated with their injectable products. This ensures that practitioners can deliver treatments effectively and safely.

  • Customer Support: Aesthetic injectable companies offer customer support services to healthcare providers and consumers, addressing inquiries, providing product information, and assisting with product usage and troubleshooting.